Oncogene-induced senescence as an initial barrier in lymphoma development

Nature

Volumn 436, Issue 7051, 2005, Pages 660-665

  Braig, Melanie ^a   Lee, Soyoung ^a   Loddenkemper, Christoph ^a   Rudolph, Cornelia ^b   Peters, Antoine H F M ^c,d   Schlegelberger, Brigitte ^b   Stein, Harald ^a   Dörken, Bernd ^a,e   Jenuwein, Thomas ^d   Schmitt, Clemens A ^a,e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^d RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^e MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION ANALYSIS; CELLS; DRUG THERAPY; GENES; GROWTH KINETICS; REACTION KINETICS;

CELLULAR SENESCENCE; HETEROCHROMATIN; LESIONS; LYMPHOMA DEVELOPMENT;

ONCOLOGY;

DOXORUBICIN; HISTONE H3; LYSINE; PROTEIN; PROTEIN P53; PROTEIN SUV39H1; UNCLASSIFIED DRUG;

MEDICINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENE LOCUS; GENETIC SUSCEPTIBILITY; GROWTH DISORDER; HETEROCHROMATIN; LYMPHOMA; METHYLATION; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE RAS; PRIORITY JOURNAL; RETINOBLASTOMA; SENESCENCE; T CELL LYMPHOMA;

ADP-RIBOSYLATION FACTORS; ANIMALS; APOPTOSIS; CELL AGING; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMAL INSTABILITY; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HETEROCHROMATIN; LYMPHOMA; METHYLATION; METHYLTRANSFERASES; MICE; MICE, TRANSGENIC; PRECANCEROUS CONDITIONS; REPRESSOR PROTEINS; TRANSGENES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA; MUS MUSCULUS;

EID: 23244461708     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature03841     Document Type: Article

References (31)

1. Campisi, J. Cellular senescence as a tumour-suppressor mechanism. Trends Cell Biol. 11, S27-S31 (2001).
2. Schmitt, C. A. Senescence, apoptosis and therapy-cutting the lifelines of cancer. Nature Rev. Cancer 3, 286-295 (2003).
3. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. &Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-602 (1997).
4. Trimarchi, J. M. &Lees, J. A. Sibling rivalry in the E2F family. Nature Rev. Mol. Cell Biol. 3, 11-20 (2002).
5. Narita, M. et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113, 703-716 (2003).
6. Rea, S. et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 406, 593-599 (2000).
7. Nielsen, S. J. et al. Rb targets histone H3 methylation and HP1 to promoters. Nature 412, 561-565 (2001).
8. Bannister, A. J. et al. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 410, 120-124 (2001).
9. Lachner, M., O'Carroll, D., Rea, S., Mechtler, K. &Jenuwein, T. Methylation of histone H3 lysine 9 creates a binding site for HPI proteins. Nature 410, 116-120 (2001).
10. Ait-Si-Ali, S. et al. A Suv39h-dependent mechanism for silencing S-phase genes in differentiating but not in cycling cells. EMBO J. 23, 605-615 (2004).
11. Haupt, Y., Harris, A. W. &Adams, J. M. Retroviral infection accelerates T lymphomagenesis in E mu-N-ras transgenic mice by activating c-myc or N-myc. Oncogene 7, 981-986 (1992).
12. Peters, A. H. et al. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 107, 323-337 (2001).
13. Kemp, C. J., Donehower, L. A., Bradley, A. &Balmain, A. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 74, 813-822 (1993).
14. Lin, A. W. et al. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signalling. Genes Dev. 12, 3008-3019 (1998).
15. Lyon, M. F. Gene action in the X-chromosome of the mouse (Mus musculus L.). Nature 190, 372-373 (1961).
16. 1NK4a expression during cellular senescence. Nature 409, 1067-1070 (2001).
17. Chang, B. D. et al. A senescence-like phenotype distinguishes tumour cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res. 59, 3761-3767 (1999).
18. Schmitt, C. A. et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109, 335-346 (2002).
19. Dimri, G. P. et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92, 9363-9367 (1995).
20. Nguyen, C. T. et al. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine. Cancer Res. 62, 6456-6461 (2002).
21. Fuks, F., Hurd, P. J., Deplus, R. &Kouzarides, T. The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. Nucleic Acids Res. 31, 2305-2312 (2003).
22. Leone, G., Voso, M. T., Teofili, L. &Lubbert, M. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Clin. Immunol. 109, 89-102 (2003).
23. Rane, S. G., Cosenza, S. C., Mettus, R. V. &Reddy, E. P. Germ line transmission of the Cdk4(R24C) mutation facilitates tumorigenesis and escape from cellular senescence. Mol. Cell. Biol. 22, 644-656 (2002).
24. Guerra, C. et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 4, 111-120 (2003).
25. Tuveson, D. A. et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5, 375-387 (2004).
26. Kim, K. C., Geng, L. &Huang, S. Inactivation of a histone methyltransferase by mutations in human cancers. Cancer Res. 63, 7619-7623 (2003).
27. Steele-Perkins, G. et al. Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein-methyltransferase superfamily. Genes Dev. 15, 2250-2262 (2001).
28. Schmitt, C. A., McCurrach, M. E., de Stanchina, E., Wallace-Brodeur, R. R. & Lowe, S. W. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 13, 2670-2677 (1999).
29. Schmitt, C. A. et al. Dissecting p53 tumour suppressor functions in vivo. Cancer Cell 1,289-298 (2002).
30. Frank, O. et al. Tumor cells escape suicide gene therapy by genetic and epigenetic instability. Blood 104, 3543-3549 (2004).
31. Hamrouni, A., Aublin, A., Guillaume, P. &Maryanski, J. L. T cell receptor gene rearrangement lineage analysis reveals clues for the origin of highly restricted antigen-specific repertoires. J. Exp. Med. 197, 601-614 (2003).